JP Morgan Maintains Overweight on AtriCure, Lowers Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Robbie Marcus maintains an Overweight rating on AtriCure (NASDAQ:ATRC) but lowers the price target from $34 to $30.
July 31, 2024 | 6:32 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan analyst Robbie Marcus maintains an Overweight rating on AtriCure but lowers the price target from $34 to $30.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal may result in a neutral short-term impact on ATRC's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100